Why Swedish Orphan Biovitrum Stock Is Back In Focus Swedish Orphan Biovitrum (OM:SOBI) has drawn fresh attention after a new partnership with Innate Pharma to run the TELLOMAK-3 Phase 3 trial for lacutamab in cutaneous T cell lymphoma. See our latest analysis for Swedish Orphan Biovitrum. The lacutamab agreement lands after a softer month for Swedish Orphan Biovitrum’s share price, which is down about 3.4% over 30 days. However, the year-to-date share price return of 33.3% and 1-year total...

Swedish Orphan Biovitrum has delivered a strong share price run over the past five years, yet its current valuation checks lean expensive rather than cheap. For investors looking at the stock today, the key issue is how to balance that track record with a low overall value score and recent deal activity. The stock has returned 157.1% over five years, which puts a clear focus on whether recent gains already reflect much of Swedish Orphan Biovitrum's potential. The licensing agreement for...

Innate is planning to begin a Phase III confirmatory trial on lacutamab as it vies for the drug’s accelerated approval in a rare subset of CTCL.

Swedish Orphan Biovitrum AB (BIOVF) reports a robust 29% revenue growth, driven by key product performances and strategic pipeline advancements, despite facing competitive and regulatory challenges.

Recent share performance and what it means for investors Swedish Orphan Biovitrum (OM:SOBI) has drawn investor attention after a period of strong price moves, with the stock showing positive returns over the past week, month, past 3 months and year to date. See our latest analysis for Swedish Orphan Biovitrum. The recent 7 day share price return of 8.33% and 30 day share price return of 7.73% sit on top of a 30.69% year to date share price return and 45.58% 1 year total shareholder return...

Swedish Orphan Biovitrum AB (BIOVF) reports a strong start to 2026 with significant growth in key product lines and strategic markets.

European Medicines Agency validates Swedish Orphan Biovitrum’s application to extend the indication of Tryngolza (olezarsen) to severe hypertriglyceridemia. Validation confirms the application is complete and moves Tryngolza into the formal EMA review process. The filing is supported by pivotal Phase 3 trial data in patients with severe hypertriglyceridemia. Swedish Orphan Biovitrum, traded as OM:SOBI, focuses on specialty care medicines, including rare diseases and complex chronic...

Swedish Orphan Biovitrum (OM:SOBI) has completed its acquisition of Arthrosi Therapeutics. The deal adds a late stage Phase 3 investigational therapy for gout to Sobi’s portfolio. The transaction strengthens Sobi’s presence in gout treatments within its rare disease focus. Sobi, listed as OM:SOBI, focuses on treatments for rare diseases and specialty care, with an emphasis on immunology and hematology. By bringing Arthrosi Therapeutics into the group, Sobi extends that model into gout, a...

What recent performance says about Swedish Orphan Biovitrum Swedish Orphan Biovitrum (OM:SOBI) has drawn attention after a relatively flat month, with a return close to 0%. This follows a modest gain over the past 3 months and mixed shorter term moves. See our latest analysis for Swedish Orphan Biovitrum. At a latest share price of SEK 328.4, Swedish Orphan Biovitrum has seen softer near term momentum, with a 1 day share price return of 1% and a 7 day share price return of 1.6%, while its 3...